02:03 PM EDT, 04/30/2024 (MT Newswires) -- Moderna's ( MRNA ) top-line sales are expected to start growing in 2025 as three products are anticipated to be approved and multiple products are expected to be launched in the next 12 to 18 months, Oppenheimer said in a note Monday.

"The [respiratory syncytial virus] vaccine approval is slated for early May 2024, while Phase 3 flu monotherapy and Phase 3 flu/COVID-19 vaccine trials should read out in 2024," the firm said.

Oppenheimer believes that investors will focus on important regulatory and clinical catalysts over the next 12 to 18 months as they "get comfortable with 2024 sales and [operating expenditure] burn guidance and the burgeoning pipeline."

The firm expects questions to focus on such catalysts on the company's Q1 earnings call on Thursday.

Oppenheimer has an outperform rating on Moderna's ( MRNA ) stock and $142 price target.

Price: 111.42, Change: -0.20, Percent Change: -0.18